

Round table discussion:

"Challenges and Opportunities in PROTAC vs Small Molecules Development"

Panelist:

Dr Rutger Folmer (Symeres, The Netherlands)



Dr Rutger Folmer is Director of Medicinal Chemistry at Symeres (previously Mercachem) in Nijmegen, The Netherlands. Rutger is responsible for a handful of teams, each running one or more medicinal chemistry projects in the hit to lead and lead opt stages.

Before joining Mercachem, Rutger worked for about 20 years at AstraZeneca in Sweden, where he was responsible for various constellations of structural biology groups, with focus on biophysical techniques and fragment-based lead generation. During later years, he also held a portfolio management role in the Respiratory, Inflammation and Autoimmunity disease area.